These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24129137)

  • 1. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
    Kiltz U; Baraliakos X; Braun J; van der Heijde D
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S47-50. PubMed ID: 24129137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
    Song IH; Haibel H; Poddubnyy D; Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S37-42. PubMed ID: 24129135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease.
    Baraliakos X; Kiltz U; Heldmann F; Sieper J; Braun J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S43-6. PubMed ID: 24129136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission and possible discontinuation of biological therapy in axial spondyloarthritis.
    Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S33-6. PubMed ID: 24129134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
    Mease P
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S59-62. PubMed ID: 24129140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Necrosis Factor Inhibitor Dose Reduction for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lawson DO; Eraso M; Mbuagbaw L; Joanes M; Aves T; Leenus A; Omar A; Inman RD
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):861-872. PubMed ID: 32166872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial.
    Pontes C; Gratacós J; Torres F; Avendaño C; Sanz J; Vallano A; Juanola X; de Miguel E; Sanmartí R; Calvo G
    Trials; 2015 Aug; 16():370. PubMed ID: 26289076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The classification and diagnostic criteria of ankylosing spondylitis.
    Raychaudhuri SP; Deodhar A
    J Autoimmun; 2014; 48-49():128-33. PubMed ID: 24534717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
    Poddubnyy D; Gensler LS
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of axial spondyloarthritis].
    Kiltz U; Baraliakos X; Braun J
    Internist (Berl); 2016 Nov; 57(11):1060-1068. PubMed ID: 27680737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis.
    Lian F; Zhou J; Wang Y; Chen D; Xu H; Liang L
    Clin Exp Rheumatol; 2018; 36(5):884-890. PubMed ID: 29652659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of methotrexate in patients with ankylosing spondylitis.
    Haibel H; Sieper J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S128-31. PubMed ID: 21044446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials.
    Shu T; Chen GH; Rong L; Feng F; Yang B; Chen R; Wang J
    Clin Exp Rheumatol; 2013; 31(5):717-22. PubMed ID: 23899710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
    Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
    Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity?
    Almirall M; Salman-Monte TC; Lisbona MP; Maymó J
    Rheumatol Int; 2015 Sep; 35(9):1565-8. PubMed ID: 25994091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating to target in axial spondyloarthritis: defining the target and the arrow.
    Wendling D
    Expert Rev Clin Immunol; 2015 Jun; 11(6):691-3. PubMed ID: 25905676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.